AUPH vs CORT

For growth investors, Aurinia Pharmaceuticals Inc.

(AUPH) is the stronger pick with 20. 4% revenue growth year-over-year, versus 12. 8% for Corcept Therapeutics Incorporated (CORT). Aurinia Pharmaceuticals Inc. (AUPH) offers the better valuation at 7. 8x trailing P/E (20. 0x forward), making it the more compelling value choice. Analysts rate Aurinia Pharmaceuticals Inc. (AUPH) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Aurinia Pharmaceuticals Inc.

(AUPH) is the cheapest at 7. 8x versus Corcept Therapeutics Incorporated at 63. 6x. On forward P/E, Aurinia Pharmaceuticals Inc. is actually cheaper at 20. 0x.

Over the past 5 years, Corcept Therapeutics Incorporated (CORT) delivered a total return of +140.

2%, compared to +31. 6% for Aurinia Pharmaceuticals Inc. (AUPH). Over 10 years, the gap is even starker: CORT returned +991. 0% versus AUPH's +552. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Aurinia Pharmaceuticals Inc.

(AUPH) is the lower-risk stock at 0. 86β versus Corcept Therapeutics Incorporated's 1. 78β — meaning CORT is approximately 106% more volatile than AUPH relative to the S&P 500. On balance sheet safety, Corcept Therapeutics Incorporated (CORT) carries a lower debt/equity ratio of 1% versus 13% for Aurinia Pharmaceuticals Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Aurinia Pharmaceuticals Inc.

(AUPH) is pulling ahead at 20. 4% versus 12. 8% for Corcept Therapeutics Incorporated (CORT). On earnings-per-share growth, the picture is similar: Aurinia Pharmaceuticals Inc. grew EPS 51. 7% year-over-year, compared to -33. 3% for Corcept Therapeutics Incorporated. Over a 3-year CAGR, AUPH leads at 28. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Aurinia Pharmaceuticals Inc.

(AUPH) is the more profitable company, earning 101. 5% net margin versus 13. 1% for Corcept Therapeutics Incorporated — meaning it keeps 101. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AUPH leads at 37. 1% versus 5. 9% for CORT. At the gross margin level — before operating expenses — CORT leads at 98. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Aurinia Pharmaceuticals Inc.

(AUPH) trades at 20. 0x forward P/E versus 138. 9x for Corcept Therapeutics Incorporated — 118. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CORT: 37. 4% to $71. 67.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Aurinia Pharmaceuticals Inc.

(AUPH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 86), +552. 4% 10Y return). Corcept Therapeutics Incorporated (CORT) carries a higher beta of 1. 78 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AUPH: +552. 4%, CORT: +991. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: AUPH is a small-cap high-growth stock; CORT is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.